BofA Expects Straumann's Q3 Growth to 'Marginally' Accelerate on 'Slightly Easier' Comparisons, Share Gains

06:35 AM EDT, 10/01/2026 (MT Newswires) -- BofA Global Research expects Straumann Holding's (STMN.SW) third-quarter sales growth to "marginally" accelerate on a quarterly basis amid expectations of "slightly easier" comparisons. The research firm said Wednesday that it expects third-quarter organic sales growth of 9%, in line with consensus estimates, supported by share gains for the dental products company's iEXCEL dental performance system and Sirios wireless intraoral digital scanner. "While macro is uncertain, we focus on what we can control, fundamentals. In our view, debate should focus on: 1) Street looks fine with 8.7% organic growth for FY26, with LSD upside potential from FX at EBIT level; 2) We see room for strong margin expansion in FY27 (above MT target of 40-50bps), driven by savings, op. leverage and mix; 3) IOS business traction to accelerate, contributing to sales/margin, and we see scope for equipment to drive sustainable and profitable growth of prosthetics," analysts wrote. Ahead of the company's earnings report on Oct. 28, BofA kept its estimates "broadly unchanged" to reflect expected topline pressures in Latin America, Europe, the Middle East and Africa, offset by "more favorable" currency developments. The research firm kept its buy rating and price objective of 124 francs on the stock, adding the company is part of its "25 for 2026" and "Europe 1 top ideas" lists.